Roche committed $1.65 billion upfront to co-develop Zealand Pharma’s amylin analog petrelintide in March 2025. The ZUPREME-1 abstract presented at ADA 2026 in New Orleans last Friday is the first detailed look at what that money bought.
I read the abstract this week. The topline numbers were already out from March: petrelintide logged a 10.7% mean weight drop at week 42 versus 1.7% on placebo. What’s new is the side-effect granularity. More than 75% of GI adverse events on petrelintide were “mild.” Nausea appeared in 19.6% of patients on the drug versus 6.2% on placebo. Vomiting was actually lower in the petrelintide arm than in controls. Only 1.5% of participants stopped due to GI side effects, against a 4.8% overall discontinuation rate.
Petrelintide’s cardiovascular data at ADA 2026 showed waist circumference shrank 7.9–10.8 cm versus 4.3 cm on placebo, high-sensitivity CRP fell 17–41% versus 6%, and triglycerides dropped 12–21% versus 9%.
That tolerability edge carries real competitive weight. GLP-1 incretin drugs like Wegovy and Zepbound are the current yardstick for obesity, but GI side effects are a documented driver of discontinuation in the real world. Petrelintide acts on amylin receptors in the brain rather than gut hormone pathways, a mechanistic distinction that may be producing a structurally cleaner side-effect profile. If it holds in phase 3, petrelintide won’t need to match Wegovy’s weight loss numbers to build a position among first-time obesity patients or those who can’t tolerate the incretin class.
Phase 3 initiation is planned for H2 2026. Worth auditing your own pipeline view on amylin before that data package lands.
Rebecca Lauren